Capital Advisors Ltd’s Neurocrine Biosciences NBIX Stock Holding History

Capital Advisors Ltd’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11K	Hold	65	–	–	﹤0.01%	843
2026 Q1	$9K	Buy	65 +61	+1,525%	+$8.09K	﹤0.01%	852
2025 Q4	$1K	Hold	4	–	–	﹤0.01%	1239
2025 Q3	$1K	Hold	4	–	–	﹤0.01%	1242
2025 Q2	$1K	Sell	4 -19	-83%	-$2.18K	﹤0.01%	1227
2025 Q1	$3K	Sell	23 -30	-57%	-$3.8K	﹤0.01%	992
2024 Q4	$7K	Buy	53 +29	+121%	+$3.59K	﹤0.01%	875
2024 Q3	$3K	Hold	24	–	–	﹤0.01%	1005
2024 Q2	$3K	Hold	24	–	–	﹤0.01%	1001
2024 Q1	$3K	Hold	24	–	–	﹤0.01%	984
2023 Q4	$3K	Buy	24 +1	+4%	+$115	﹤0.01%	950
2023 Q3	$3K	Buy	+23	New	+$2.42K	﹤0.01%	943
2023 Q1	–	Sell	-51	Closed	-$6K	–	1428
2022 Q4	$6K	Buy	51 +3	+6%	+$351	﹤0.01%	631
2022 Q3	$5K	Buy	+48	New	+$4.87K	﹤0.01%	642
2022 Q2	–	Sell	-7	Closed	-$1K	–	1207
2022 Q1	$1K	Buy	7 +5	+250%	+$424	﹤0.01%	754
2021 Q4	$0	Buy	+2	New	+$184	﹤0.01%	888

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital Advisors Ltd's NBIX Position: Q2 2026 in Review

Capital Advisors Ltd held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 65 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #843.

Capital Advisors Ltd first reported a position in NBIX in Q4 2021 and has held it in 16 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Capital Advisors Ltd held 65 shares of Neurocrine Biosciences worth $11K as of Q2 2026.
Capital Advisors Ltd left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #843 holding.
Capital Advisors Ltd first reported a position in Neurocrine Biosciences in Q4 2021 and has held it in 16 quarters since.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.